Cited by 215Erythropoietin and Anemia TreatmentProstate Cancer Treatment and ResearchHormonal and reproductive studies

The DOI matches its Crossref record.

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade

STRUM, S.B., McDERMED, J.E., SCHOLZ, M.C., JOHNSON, H., TISMAN, G.·1997·British Journal of Urology

DOI 10.1046/j.1464-410x.1997.00234.x

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To describe the incidence, time to onset and extent of anaemia occurring in patients with prostate cancer receiving combined hormone blockade (CHB) and the timing and extent of recovery from anaemia in those patients where CHB was discontinued. PATIENTS AND METHODS: Patients with prostate cancer were evaluated prospectively by physical examination and laboratory tests at baseline and at routine intervals while receiving CHB. Of 142 patients who received CHB, 133 were evaluable for the assessment of anaemia; CHB was discontinued in 76 patients, of whom 64 were assessable for recovery from their anaemia. RESULTS: Haemoglobin levels declined significantly in all patients from a mean baseline of 149 g/L to means of 139 g/L, 132 g/L and 131 g/L at 1, 2 and 3 months, respectively. Haemoglobin levels continued to decline during CHB to a mean nadir of 123 g/L at a mean of 5.6 months of CHB, representing a mean absolute haemoglobin decline at nadir of 25.4 g/L. In 120 of the 133 (90%) patients, the relative decline in haemoglobin at nadir was > or = 10% and was > or = 25% in 17 (13%) others, representing a mean absolute haemoglobin decline in this subset of 42.7 g/L. Significant symptoms related to anaemia occurred in 17 patients (13%). Anaemia and symptoms in these patients were easily corrected with the subcutaneous administration of recombinant human erythropoietin. CONCLUSIONS: The anaemia associated with androgen deprivation is significant and occurs routinely in men receiving CHB. It is normochromic, normocytic, temporally-related to the initiation of androgen blockade and usually resolves after CHB is discontinued. We suggest that patients receiving CHB undergo haematological testing at baseline, 1-2 months after initiating CHB and periodically thereafter. Patients developing anaemia should be questioned about symptoms reflecting physiological compromise (e.g. angina, dyspnoea on exertion). In the absence of other causes, CHB should be suspected in the development of anaemia in patients receiving this treatment.

Integrity signals

Registry

Crossref · 10.1046/j.1464-410x.1997.00234.x

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 215

My Get Up and Go Got Up and Went: Fatigue in People With Cancer
Nail, L. M. (2004) · JNCI Monographs · doi:10.1093/jncimonographs/lgh021 · Cited by 21
“72 Journal of the National Cancer Institute Monographs No. 32, 2004 (37, 38 ).”
Background
Intermittent Versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer
Klotz, L. H. (2013) · Current Urology Reports · doi:10.1007/s11934-013-0325-x · Cited by 19
“032) for osteoporosis in men on continuous androgen deprivation (CAD) compared to IAD [27].”
Result
COMPLEMENTARY AND ALTERNATIVE THERAPIES FOR ADVANCED PROSTATE CANCER
Smith, M. R. (2001) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70232-x · Cited by 19
Mature Results of the Ottawa Phase II Study of Intermittent Androgen-Suppression Therapy in Prostate Cancer: Clinical Predictors of Outcome
Malone, S. C., Perry, G., Eapen, L. J., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.12.072 · Cited by 19
Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery
Chander, S., Choo, R., Danjoux, C., Morton, G., Pearse, A., Deboer, G., Szumacher, E., Loblaw, A., Cheung, P., & Woo, T. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.11.008 · Cited by 18
Oestrogen‐deficiency inducing haematopoiesis dysfunction via reduction in haematopoietic stem cells and haematopoietic growth factors in rats
Qiu, X., Yuan, X., Jin, X., He, X., Zhu, L., & Zhao, X. (2012) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2012.00815.x · Cited by 18
“Similarly, anaemia as a side effect of anti-androgen therapy (Strum et al. 1997) has been observed for many years and now androgen is usually used by patients with aplastic anaemia.”
Background
Hematologic Toxicity of Conformal Radiotherapy and Intensity Modulated Radiotherapy in Prostate and Bladder Cancer Patients
Miszczyk, M., & Majewski, W. (2018) · PubMed · doi:10.22034/apjcp.2018.19.10.2803 · Cited by 18
“The androgen deprivation therapy which was generally implemented in a group of patients with high-risk prostate cancer might have some impact on hematologic parameters behavior, too (Strum et al., 1997; Gruca et al., 2012).”
Background
Role of Androgen Deprivation Treatment in Patients With Castration-Resistant Prostate Cancer, Receiving Docetaxel-Based Chemotherapy
Lee, J., Kim, J. E., Ahn, J., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181d2ed7d · Cited by 17
Androgen deprivation treatment in prostate cancer
Thomas, B. C., & Neal, D. E. (2013) · BMJ · doi:10.1136/bmj.e8555 · Cited by 17
Preventing and treating the complications of hormone therapy
Kumar, R., Barqawi, A. B., & Crawford, E. D. (2005) · Current Urology Reports · doi:10.1007/s11934-005-0010-9 · Cited by 15
“The etiology is caused by the lack of stimulation of erythroid stem cells by testosterone and dihydrotestosterone and deficiency of erythropoietin [ 44 ].”
Background
Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer
Shahinian, V. B., & Kuo, Y. (2015) · BMC Urology · doi:10.1186/s12894-015-0020-y · Cited by 14
“Recognition of the impact of ADT on quality of life, anemia and osteoporosis was evident as early as the 1990s [20-23].”
Background
Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study
Timilshina, N., Hussain, S., Breunis, H., & Alibhai, S. M. H. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-1023-6 · Cited by 14
“In several studies of men with non-metastatic prostate cancer and normal hemoglobin levels at baseline, ADT was associated with a significant decline in hemoglobin after initiation of therapy [8, 21, 24 ].”
BackgroundResultInfluential
Toxicological evaluation of Picralima nitida in rodents
Awodele, O., Coulidiaty, A. G. V., Afolayan, G. O., et al. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.03.008 · Cited by 13
Hormonal treatment for prostate cancer
Harris, K. A., & Small, E. J. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.3.493 · Cited by 13
“However, response rates tend to be low in the order of 10% or less [126-129].”
Background
Hormonal therapy for prostate cancer: primum non nocere
MILBANK, A. J., Dreicer, R., & Klein, E. A. (2002) · Urology · doi:10.1016/s0090-4295(02)01867-8 · Cited by 13
Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer
Kaisary, A. V. (2005) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500800 · Cited by 13
Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Rich, B. J., Montoya, C., Jin, W. H., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.05.040 · Cited by 12
Improving selective androgen receptor modulator discovery and preclinical evaluation
Jones, J. O. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903206957 · Cited by 12
The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy ± neoadjuvant androgen deprivation
Parker, C. C., Warde, P. R., Norman, A. R., Panzarella, T., Catton, C., Horwich, A., Huddart, R. A., & Dearnaley, D. P. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00821-6 · Cited by 12
Effects of radiation and total androgen blockade on serum hemoglobin, testosterone, and erythropoietin in patients with localized prostate cancer
Golfam, M., Samant, R., Eapen, L., & Malone, S. (2012) · Current Oncology · doi:10.3747/co.19.963 · Cited by 11
Exercise After Prostate Cancer Diagnosis
Mina, D. S., Ritvo, P., SEGAL, R. J., Culos-Reed, N. S., & Alibhai, S. M. H. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1173-5_7 · Cited by 11
“The physical, functional, and psychological detriments that are associated with ADT are due to prolonged periods of hypogonadism, which causes reductions in Hb, BMD, lean body mass, and increases in fat mass [17–24].”
Background
Radioisotopic treatment of bone pain from metastatic prostate cancer
Sartor, O. A. (2003) · Current Oncology Reports · doi:10.1007/s11912-003-0119-2 · Cited by 11
“Clinicians should also be aware that significant anemia may develop in patients treated with androgen deprivation therapies [ 5 ].”
Background
Early versus delayed endocrine therapy for prostate cancer
Schröder, F. H. (2007) · Endocrine Related Cancer · doi:10.1677/erc-06-0022 · Cited by 11
“Fatigue has been related to anemia by Strum et al. (1997), other authors found an eight times increased rate of depression with respect to US national averages (Pirl et al. 2002).”
Result
A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial
Black, P. C., Basen-Engquist, K. M., Wang, X., Swartz, R. J., Eddings, T., Matin, S. F., Swanson, D. A., Wood, C. G., Pisters, L. L., Babaian, R. J., et al. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06846.x · Cited by 11
American Sexual Offender Castration Treatment and Legislation
del Busto, E., & Harlow, M. C. (2011) · Wiley eBooks · doi:10.1002/9781119990420.ch29 · Cited by 10
Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
Dason, S., Allard, C. B., Wang, J. G., et al. (2014) · PubMed · Cited by 9
Serum testosterone level after intensity-modulated radiotherapy in low-risk prostate cancer patients: does testicular dose correlate with testosterone level?
Ishiyama, H., Teh, B. S., Paulino, A. C., Yogeswaren, S. T., Mai, W.-Y., Xu, B., & Butler, E. B. (2012) · Journal of Radiation Oncology · doi:10.1007/s13566-012-0007-1 · Cited by 9
“Aside from the abovementioned controversy, some consequences of hypogonadism also caused by impairment of TE secretion would be significant including anemia [6],”
Background
Assessment of an ethanolic seed extract of Picralima nitida ((Stapf) Th. and H. Durand) on reproductive hormones and its safety for use
Otoo, L., Koffuor, G. A., Ansah, C., et al. (2015) · Journal of Intercultural Ethnopharmacology · doi:10.5455/jice.20151030085004 · Cited by 9
“Androgens are known for their ability to stimulate erythropoeisis and anemia is associated with androgen deprivation [16].”
Background
Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
Jang, H. S., Koo, K. C., Cho, K. S., & Chung, B. H. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.5.1070 · Cited by 9
“It has been reported that continuation of ADT is associated with serious health problems–coronary heart disease, myocardial infarction, fracture, anemia, and diabetes–and thus can affect the survival outcomes of patients.(15-18) In terms of survival advantage, the benefits of concurrent administration of ADT in CRPC p…”
Background
Iron and Testosterone: Interplay and Clinical Implications
Gabrielsen, J. S. (2017) · Current Sexual Health Reports · doi:10.1007/s11930-017-0097-2 · Cited by 9
Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With Radiotherapy
Denham, J. W., & Steigler, A. (2013) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.01.008 · Cited by 8
Promoting Wellness for Patients on Androgen Deprivation Therapy: Why Using Numerous Drugs for Drug Side Effects Should Not Be First-Line Treatment
Moyad, M. A., & Roach, M. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.05.001 · Cited by 9
Management of Anaemia in Prostate Cancer
Colloca, G. A., Venturino, A., Vitucci, P., & Gianni, W. (2009) · Cancer Investigation · doi:10.3109/07357900903124480 · Cited by 7
“Castration-related anaemia (CRA) has been extensively reported, and consists of a hemoglobin reduction of 7% the basal level on a median time of 40 days from beginning of castration (38), is more frequent after complete androgen blockade (39) even if an effect of antiandrogens is uncertain (40, 41).”
Background
LEUPROLIDE CAUSES PURE RED CELL APLASIA
Maeda, H. A., Arai, Y., Aoki, Y., et al. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)62939-2 · Cited by 6
Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
Liu, J., Liu, Y.-P., Chuang, H.-C., Wu, C., Su, Y., & Hsu, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229263 · Cited by 6
“[8,9] Non-Hodgkin’s lymphoma (NHL) is one of the most common hematologic malignancies worldwide, with an incidence significantly higher in men than in women.”
Background
Testosterone Recovery and Quality of Life of Japanese Patients After Short‐Term Neoadjuvant Androgen Deprivation Therapy With Low‐Dose‐Rate Brachytherapy for Prostate Cancer
Onishi, K., Nakai, Y., Tachibana, A., Nishimura, N., Maesaka, F., Tomizawa, M., Morizawa, Y., Hori, S., Gotoh, D., Miyake, M., et al. (2025) · International Journal of Urology · doi:10.1111/iju.70018 · Cited by 5
“However, long-term administration of ADT can cause various adverse events, such as hot flashes [3], anemia [4], osteoporosis [5], metabolic syndrome [6], and deterioration of sexual function [7].”
Darbepoetin Alfa Administered Every 4 Weeks for Anemia in Patients with Advanced Prostate Cancer
Beer, T. M., Bergenstock, M., Birt, K., & Higano, C. S. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.012 · Cited by 5
Transfusion-Dependent Anemia After Initiation of Androgen Deprivation Therapy for Metastatic Prostate Cancer
Curtis, K. K., Pruthi, R. K., Fonseca, R., et al. (2007) · Urology · doi:10.1016/j.urology.2007.07.030 · Cited by 5
Clinical significance of androgen secretion disorders in men with a malignancy
Wiechno, P., Poniatowska, G., Michalski, W., Kucharz, J., Sadowska, M., Jońska‐Gmyrek, J., Nietupski, K., Rzymowska, J., & Demkow, T. (2017) · Medical Oncology · doi:10.1007/s12032-017-0982-6 · Cited by 5
“On ADT, haemoglobin concentration in men with nonmetastatic prostate cancer is gradually decreasing, usually by 1–2 g/dL [64, 65].”
Background
Androgen deprivation therapy and the risk of iron-deficiency anaemia among patients with prostate cancer: a population-based cohort study
Wu, F.-J., Li, I., Chien, W., Shih, J., Lin, Y., Chuang, C.-M., Cheng, Y., & Kao, L. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034202 · Cited by 5
Screening for Prostate Cancer: An Update of the Evidence
Harris, R., & Lohr, K. N. (2002) · Cited by 5
Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy
Pai, H. H., Ludgate, C. M., Pickles, T., Paltiel, C., Agranovich, A., Berthelet, E., Duncan, G. G., Kim‐Sing, C., Kwan, W., Lim, J. T. W., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.02.008 · Cited by 5
The Future of Endocrine Treatment in Early Prostate Cancer: Concluding Remarks
Schröder, F. H. (1999) · European Urology · doi:10.1159/000052340 · Cited by 5
“The decrease in bone mineral density which leads to osteoporotic fractures is clearly related to the decrease of circulating androgens and oestrogens and is therefore more of a problem with treatments that lower circulating testosterone levels.Anaemia caused by low androgen levels has been monitored in 133 patients wi…”
Background
Management of prostate cancer. Part 3: metastatic disease
Shah, J., Khaksar, S., & Sooriakumaran, P. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.813 · Cited by 5
Anemia y hormonoterapia neoadyuvante en la cirugía radical del cáncer de próstata localizado
Arango, O., Garín, J. A. L., Bielsa, Ó., Garreta, J. G., & Gelabert-Más, A. (2001) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(01)72581-8 · Cited by 4
Androgen deprivation therapy for prostate cancer and its complications
Pope, A., & Abel, P. D. (2010) · Trends in Urology Gynaecology & Sexual Health · doi:10.1002/tre.150 · Cited by 4
Short-Term Haematogical Effects of Androgen Deprivation and Radiotherapy in Prostate Cancer Patients
Swanson, G. P., Hammonds, K. A. P., & Jhavar, S. G. (2021) · Open Journal of Urology · doi:10.4236/oju.2021.114011 · Cited by 4
Rapid Review of Breast Cancer Treatment Side Effects and Dietary Supplement/Integrative Options from A to Z: What Helps, Harms, or Does Nothing?
Moyad, M. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-23422-9_7 · Cited by 5
Preventing and Treating the Side Effects of Testosterone Inactivating Pharmaceuticals in Men with Prostate Cancer
Guess, B. W., Scholz, M. C., & Lam, R. Y. (2006) · Seminars in Preventive and Alternative Medicine · doi:10.1016/j.spre.2005.12.003 · Cited by 4
Self-citation
Endocrine Manipulation
Wilson, S., & Crawford, E. D. (2008) · Springer eBooks · doi:10.1007/978-1-84628-738-1_30 · Cited by 4
Therapieoptionen des hormonrefraktären Prostatakarzinoms
Heidenreich, A., & Ohlmann, C. (2005) · Der Urologe · doi:10.1007/s00120-005-0928-z · Cited by 4
DRUGS USED IN CANCER CHEMOTHERAPY
(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53267-1.50004-6 · Cited by 4
The Use of Complete Blood Count as Inflammatory Biomarkers in Patients with Colorectal Cancers in Enugu State University of Science and Technology Teaching Hospital, Parklane Enugu
Clara, N. S., Finbarrs-Bello, E., Ugwuene, F. O., et al. (2022) · Asian Journal of Medicine and Health · doi:10.9734/ajmah/2022/v20i12773 · Cited by 3
“In 2017 some works reported that these inflammatory cytokines also impairs iron metabolism which results in reduced serum iron levels and iron retention within the reticuloendothelial system (RES)[52].”
BackgroundResultInfluential
Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial
Nabid, A., Carrier, N., Martin, A., Bahary, J.-P., Vavassis, P., Vass, S., Bahoric, B., Archambault, R., Vincent, F., Bettahar, R., et al. (2024) · Quality of Life Research · doi:10.1007/s11136-024-03843-5 · Cited by 3
“…use of ADT may result in sustained biochemical castration resulting in hypogonadal ill effects, including hot flashes [ 4], fatigue [ 5 ], anemia [ 6], decrease muscle strength, increase body fat [ 7, 8 ], depression, anxiety [ 9, 10], metabolic syndromes [ 11 ], decrease penile and testicular…”
Management of fatigue and anaemia in men treated with androgen deprivation therapy
Rodríguez‐Vida, A., Chowdhury, S., & Chowdhury, S. (2014) · Trends in Urology & Men s Health · doi:10.1002/tre.396 · Cited by 3
Pure red cell aplasia in a prostate cancer patient treated with leuprolide acetate and chlormadinone acetate
Kobayashi, M., Nukui, A., & Morita, T. (2005) · International Journal of Urology · doi:10.1111/j.1442-2042.2005.01195.x · Cited by 3
Anemia Related to Hormonal Ablation Therapy for Prostate Cancer
Oh, W. K. (2001) · The Prostate Journal · doi:10.1046/j.1525-1411.2001.003001014.x · Cited by 3
Medical and Psychosocial Issues in Prostate Cancer Survivors
Krupski, T. L., & Litwin, M. S. (2007) · Springer eBooks · doi:10.1007/978-0-387-68265-5_12 · Cited by 3
Modern approaches to the treatment of anemia of malignant neoplasms
Pecherskikh, A. A., Parfenova, T., Pinchuk, T. V., et al. (2024) · Medical alphabet · doi:10.33667/2078-5631-2024-13-21-26 · Cited by 2
Bisphosphonates for Prevention and Treatment of Bone Metastases
Saylor, P. J., & Smith, M. R. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_24 · Cited by 2
“Finally, androgen deprivation routinely causes a mild normocytic anemia [15].”
Background
Prise en charge des effets secondaires de l’hormonoprivation androgénique
Irani, J. (2008) · ONCOLOGIE · doi:10.1007/s10269-008-0963-7 · Cited by 2
“L’anémie répond bien à l’interruption des analogues en dehors de facteurs étiologiques précis cités au-dessus [28].”
Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen‐deprivation therapy for hormone‐naïve bone‐metastatic prostate cancer
Ebbinge, M., Berglund, A., Varenhorst, E., Hedlund, P. O., Sandblom, G., & the Scandinavian Prostate Cancer Group (SPCG)‐5 Study Group (2018) · British Journal of Urology · doi:10.1111/bju.14227 · Cited by 2
Locally Advanced Prostate Cancer Biochemical Recurrence after Radiotherapy: Use of Cyclic Androgen Withdrawal Therapy
Crook, J. M. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_39 · Cited by 2
[Anaemia and prostatic cancer].
Boustany, R., & Zerbib, M. (2005) · PubMed · Cited by 2
Management of Newly Diagnosed Metastatic Disease
Cowey, C. L., & Hutson, T. E. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-259-9_22 · Cited by 1
Gestion des effets secondaires de la suppression androgénique
Lebrét, T., & Arnaud Mejean, D. (2008) · The French Journal of Urology · doi:10.1016/s1166-7087(08)74564-0 · Cited by 1
Clinical Pearls in General Internal Medicine
Bundrick, J. B., & Litin, S. C. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0462 · Cited by 1
“6 g/dL in another.(8) The mean corpuscular volume remains normocytic.”
Background
Complementary and Alternative Medicine and Lifestyle Changes and Prostate Cancer
Moyad, M. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8492-9_7 · Cited by 1
Side Effects of Medical Cancer Therapy in Genitourinary Malignancies
TOMBAL, B. F., Remacle, C., & Vubu, M. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_6 · Cited by 1
Robust Analytical Method for Iron Estimation by Experimental Design Approach
Mahajan, M. R., & Patil, D. D. (2020) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.54.2.52 · Cited by 1
“1 ml) and pH of the solution (2-9) with the absorbance 0.”
Background
Genitourinary Cancer
TOMBAL, B. F. (2012) · Springer eBooks · doi:10.1007/978-0-85729-787-7_6 · Cited by 1
ADVERSE EFFECTS OF ANDROGEN DEPRIVATION THERAPY ON PATIENTS WITH PROSTATE CANCER AND ITS EFFECT ON OVERALL SURVIVAL
Shimabukuro, T., Ohmi, C., Nagamitsu, R., Shiraishi, K., & Matsuyama, H. (2021) · The Japanese Journal of Urology · doi:10.5980/jpnjurol.112.81 · Cited by 1
Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy
Abildgaard, J., Stroomberg, H. V., Bang, A. K., Albrethsen, J., Kruuse, L. S., Juul, A., Brasso, K., Røder, M. A., & Jørgensen, N. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0246 · Cited by 1
Managing Symptoms over Time
Kouri, E. M., & Keating, N. L. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1348-7_3 · Cited by 1
“The decrease in serum androgens has also been linked to significant clinical manifestations including osteopenia and osteoporosis [235], fractures [236], anemia [237], and increased body mass index [238].”
Background
Evaluating the Effects of Prostate Radiotherapy Intensified with Pelvic Nodal Radiotherapy and Androgen Deprivation Therapy on Myelosuppression: Single-Institution Experience
Katib, Y., Tisseverasinghe, S., Gerard, I. J., et al. (2024) · Current Oncology · doi:10.3390/curroncol31090402 · Cited by 1
Side Effects and Management of ADT for Prostate Cancer
Chung, M. S., & Lee, S. H. (2018) · Springer eBooks · doi:10.1007/978-981-10-6943-7_19 · Cited by 1
PROSTATE CANCER
Holstein, S. A., & Hohl, R. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50071-8 · Cited by 1
Prostate Cancer: Immediate vs. Deferred Treatment
Underwood, M. A., & Kirk, D. (2006) · Springer eBooks · doi:10.1007/1-84628-015-x_6 · Cited by 1
Medical Approach to Advanced Prostate Cancer in Older Patients
Falci, C., Brunello, A., Basso, U., Roma, A., & Monfardini, S. (2008) · Aging Health · doi:10.2217/1745509x.4.5.481 · Cited by 1
Prostate gland disease
Huynh, P., Hollander, J. B., & Diokno, A. C. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2261-9.50046-x · Cited by 1
Prostate Cancer Emergencies
Hickerton, B., Abdulmajed, M. I., Arya, M., et al. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_86
Les effets secondaires de l’hormonothérapie et leur gestion
Hennequin, C., Mongiat-Artus, P., Quéro, L., Pouessel, D., & Culine, S. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2124-2
“Une baisse du taux de l’hémoglobine d’un ou deux points n’est pas rare en cas de déprivation androgénique prolongée [48].”
Resistance exercise in men receiving androgen deprivation therapy for prostate cancer
Galvao, D. A. (2006) · Australasian Journal of Paramedicine
Clinical pearls in general internal medicine
Bundrick, J. B., & Litin, S. C. (2015) · Disease-a-Month · doi:10.1016/j.disamonth.2015.04.002
Screening and treatment for prostate cancer: The evidence and implications for practice
Steggall, M. J., & Lee, A. (2004) · Journal of research in nursing · doi:10.1177/136140960400900502
Recombinant human erythropoietin (rhEPO) in the management of anemia and fatigue associated with solid tumors
Davidson, T. G. (1998) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155298004004041
Complicações da terapêutica de privação androgénica no cancro da próstata / uma revisão
Rolim, N., Lopes, F. R. G., Rodrigues, T., dos Santos, J. C. A., Mota, R. L., Covita, A., Soares, M. J., Monteiro, P., Canhoto, A., Nogueira, R., et al. (2014) · Acta Urológica Portuguesa · doi:10.1016/s2341-4022(14)50055-9
Side Effects and Complications of Androgen Deprivation in Prostate Cancer Patients
Fernandez‐Castro, G. (2010) · The Open Prostate Cancer Journal · doi:10.2174/1876822901003010029
Male hormonal contraception: a safe option?
Walton, M. J., & Anderson, R. A. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.1.25
Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer
Nambudiri, V. E., & Keating, N. L. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.35
Aktuelle Optionen der taxanbasierten Chemotherapie des hormonrefrakt�ren Prostatakarzinoms
Heidenreich, A., Wolf, J., & Miller, K. (2004) · Der Onkologe · doi:10.1007/s00761-004-0803-3
Cardiovascular risk associated with androgen deprivation therapy.
Leja, M. J., & Yeh, E. T. H. (2010) · PubMed
When to choose radiotherapy for prostate cancer, and what technique?
Denham, J. W. (2015) · NOVA (University of Newcastle Australia)
A PROSPECTIVE STUDY TO EVALUATE THE EFFECTS OF SODIUM ALENDRONATE (AN ORAL BISPHOSPHONATE) ON BONE MINERAL DENSITY (BMD) IN PATIENTS WITH CARCINOMA PROSTATE TREATED WITH HORMONAL MANIPULATION
Arun, J. S., & Puja, J. (2017) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2017/514
Effect of maximal androgen blockade therapy on hematological, biochemical and bone density in locally advanced prostate cancer
Demirelli, E., Haliloğlu, A. H., Gülpınar, Ö., Sönmez, M. G., Bedük, Y., & Küpeli, S. (2018) · Acta Medica Alanya · doi:10.30565/medalanya.407858
Prostate Cancer: Immediate vs. Deferred Treatment
Kirk, D. (2002) · doi:10.1002/9780470757147.ch11
The Patient Journey in Prostate Cancer: Key Points for Nurses
Remacle, C. (2019) · Principles of specialty nursing · doi:10.1007/978-3-319-76457-3_13
Iron, TIBC and Ferritin Levels Correlation with Testosterone Deficient Males in Dhaka, Bangladesh
Sarkar, A., Asaduzzaman, M., Juliana, F. M., Islam, M. J., Liza, M. Y. A., Das, B. C., Tanzid, M., Hosen, M. S., & Islam, M. T. (2020) · Journal of Health, Medicine and Nursing · doi:10.7176/jhmn/81-10
“75 deficiency.[17] It is fascinating to take note of that the hours of the most elevated testosterone levels concur with the hours of the most elevated iron interest in people.”
Background
Prostatakarzinom
Börgermann, C., Chun, F. K. ‐., Bastian, P. J., Fischer, K., Fornara, P., Fröhner, M., Graefen, M., Haese, A., Hammerer, P. G., Heine, K., et al. (2014) · Springer eBooks · doi:10.1007/978-3-642-35032-0_24 · Cited by 1
LEUPROLIDE CAUSES PURE RED CELL APLASIA
Maeda, H. A., Arai, Y., Aoki, Y., et al. (1998) · The Journal of Urology · doi:10.1097/00005392-199808000-00061

Authors: STRUM, S. B., McDERMED, J. E., SCHOLZ, M. C., JOHNSON, H., & TISMAN, G.
Affiliations: Marina Del Rey Hospital (US)
Corresponding author: STRUM, S.B.
ORCID: STRUM, S.B.
TISMAN, G.
Venue: British Journal of Urology
Publisher: Wiley
Published: 1997-06
Volume: 79
Issue: 6
Pages: 933-941
ISSN: 0007-1331 (ISSN-L)
DOI: 10.1046/j.1464-410x.1997.00234.x
OpenAlex: W2050743117
Cited by: 215
References: 0
Citations by year: 2026: 1 · 2025: 2 · 2024: 5 · 2022: 3 · 2021: 2 · 2020: 6 · 2019: 4 · 2018: 8 · 2017: 6 · 2016: 2 · 2015: 9 · 2014: 6 · 2013: 10 · 2012: 16
FWCI: 2.50
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2341 d)
Locations: British Journal of Urology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords: anemia, prostate cancer, androgen deprivation therapy, haemoglobin decline, normocytic normochromic anemia, recombinant human erythropoietin, hematological monitoring
MeSH terms: Age Factors, Aged, Anemia, Anilides, Antineoplastic Combined Chemotherapy Protocols, Flutamide, Hemoglobins, Humans, Male, Nitriles, Prospective Studies, Prostatic Neoplasms, Testosterone, Time Factors, Tosyl Compounds, Finasteride

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks